Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Mitral valve repair by experienced surgeons improves the survival rate of patients

Superior surgical techniques used in centres such as the University of Ottawa Heart Institute (UOHI) to fix a faulty heart valve flap, eliminate severe blood leakage and other serious cardiac conditions are highlighted as an expert guide to physicians and featured today in one of medicine's most prestigious journals.

4 Dec 2009

Weight loss - an effective treatment for sleep apnoea in obese men

For obese men, a dramatic weight loss can be an effective way to improve moderate to severe sleep apnoea, scientists at the Swedish medical university Karolinska Institutet report. Those with severe sleep apnoea when the study began benefited most from weight loss.

4 Dec 2009

Findings suggest severity of atherosclerosis depends on the rate of white blood cell migration

By measuring the total gene activity in organs relevant for coronary artery disease (CAD), scientists at the Swedish medical university Karolinska Institutet have identified a module of genes that is important for the recruitment of white blood cells into the atherosclerotic plaque.

4 Dec 2009

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Isis Pharmaceuticals, Inc. announced today that it has added two new drugs to its development pipeline, ISIS-FXIRx and ISIS-SMNRx.

4 Dec 2009

Geisinger Health System and Philips VISICU team up to launch eICU Program

Geisinger Health System recently signed an agreement with Philips VISICU, to launch an eICU Program® that will enhance physicians' ability to care for Geisinger's sickest patients.

4 Dec 2009

Study shows younger, female and Hispanic stroke survivors are less likely to take antithrombotic medications

People who have had an ischemic stroke are at higher lifetime risk for another stroke, but several types of medication can reduce that risk. One of the simplest regimens involves antithrombotic medications, otherwise known as blood thinners, of which the most common is aspirin.

3 Dec 2009

Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2291.

3 Dec 2009

China's SFDA initiates quality investigation of Simcere Pharmaceutical Group subsidiary's rabies vaccine

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported that China's State Food and Drug Administration ("SFDA") has initiated a comprehensive investigation into quality issues regarding human use rabies vaccine (vero cell) manufactured by Simcere's subsidiary Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen").

3 Dec 2009

Lunasin may have important health benefits, two new studies report

Two new University of Illinois studies report that lunasin, a soy peptide often discarded in the waste streams of soy-processing plants, may have important health benefits that include fighting leukemia and blocking the inflammation that accompanies such chronic health conditions as diabetes, heart disease, and stroke.

3 Dec 2009

Huntington Memorial Hospital's stroke program receives Gold Seal of Approval

Huntington Memorial Hospital's stroke program has received the Gold Seal of Approval from the Joint Commission, designating the hospital a primary stroke center. This means Huntington will join the network of "approved stroke center" hospitals throughout Los Angeles County.

3 Dec 2009

Intracranial endovascular procedures will grow at over 5% through 2014 in the US, says MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, intracranial endovascular procedures to treat aneurysms will grow at over 5% through 2014 in the US. MRG's new US Markets for Transcatheter Embolization and Occlusion Devices 2010 report finds that technological advancements in embolization coils as well as imaging and coiling-assist technology will continue to drive growth in aneurysm coiling procedures.

3 Dec 2009

MSC's Quality Initiative Programs to be highlighted at the 2009 IHI National Forum

Medical Simulation Corporation (MSC) will highlight its full menu of Quality Initiative Programs at the 2009 IHI National Forum, December 7-9, 2009, in Orlando, Florida. MSC is the first simulation company to introduce simulation-based education programs that help healthcare providers bridge the gap between measurement and achievement of publicly reported patient safety and quality initiatives.

2 Dec 2009

FDA approves revised clinical trial protocol for CytRx' arimoclomol

CytRx Corporation, a biopharmaceutical company, is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), following the U.S. Food and Drug Administration’s (FDA) acceptance of a revised clinical trial protocol.

2 Dec 2009

Jiangsu Yanshen Biological Technology Stock suspends production of all products

Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported that its subsidiary Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen") has suspended production of all its products in order to conduct an internal inspection and improve its quality control systems.

2 Dec 2009

Toshiba’s new CT system allows physicians to reduce diagnosis time for stroke

When a patient comes to a hospital’s emergency department (ED) exhibiting stroke symptoms, it can take hours to diagnose and treat the patient when time is of the essence. Toshiba’s Aquilion® ONE dynamic volume CT system has the ability to improve the quality of life for patients with neurological symptoms, especially related to stroke, by reducing diagnosis time to minutes.

2 Dec 2009

Roche announces results of phase III taspoglutide study in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s research and developed by Roche.

2 Dec 2009

Boehringer Ingelheim to announce positive results from its RE-COVER study

Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.

2 Dec 2009

New preventive screening packages for heart disease

HealthYes!®, a leading mobile medical screening provider, is offering several new preventive screenings directly focused on heart disease. The new tests include: a six-lead electrocardiogram (EKG), cholesterol finger-stick, and 10-year Framingham Cardiac Risk Score as well as diabetes and liver function testing.

2 Dec 2009

Overall use of blood-thinning agents not improving despite more options

Since 1999, stroke survivors have been advised to use aspirin, prescription antiplatelet agents, or prescription anticoagulants to help avoid another stroke. Many large surveys of the U.S. population have reported the use of aspirin for secondary prevention, but commonly combine people with stroke and coronary artery disease, and only rarely report the use of antithrombotic agents other than aspirin.

2 Dec 2009

Antipsychotic medications increase the levels of inflammation markers, find researchers

Overall, antipsychotic medications are reasonably effective, and fairly well tolerated treatments for mood and psychotic disorders. However, treatment with a number of antipsychotic medications is associated with weight gain, and for some, hyperglycemia and hyperlipidemia.

2 Dec 2009

Stroke News and Research

Further Reading

Mitral valve repair by experienced surgeons improves the survival rate of patients

Weight loss - an effective treatment for sleep apnoea in obese men

Findings suggest severity of atherosclerosis depends on the rate of white blood cell migration

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Geisinger Health System and Philips VISICU team up to launch eICU Program

Study shows younger, female and Hispanic stroke survivors are less likely to take antithrombotic medications

Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial

China's SFDA initiates quality investigation of Simcere Pharmaceutical Group subsidiary's rabies vaccine

Lunasin may have important health benefits, two new studies report

Huntington Memorial Hospital's stroke program receives Gold Seal of Approval

Intracranial endovascular procedures will grow at over 5% through 2014 in the US, says MRG

MSC's Quality Initiative Programs to be highlighted at the 2009 IHI National Forum

FDA approves revised clinical trial protocol for CytRx' arimoclomol

Jiangsu Yanshen Biological Technology Stock suspends production of all products

Toshiba’s new CT system allows physicians to reduce diagnosis time for stroke

Roche announces results of phase III taspoglutide study in diabetes patients

Boehringer Ingelheim to announce positive results from its RE-COVER study

New preventive screening packages for heart disease

Overall use of blood-thinning agents not improving despite more options

Antipsychotic medications increase the levels of inflammation markers, find researchers

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News